Agenus | AGEN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.63B 54M 2026-06
Agenus USD 6.21M 4.34M 2026-03
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Celldex Therapeutics USD 13.1M 1.65M 2026-06
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.42B 381M 2026-06
Jiangsu Hengrui CNY 2.81B 191.05M 2026-03
Karyopharm Therapeutics USD 10.42M 861K 2026-03
MacroGenics USD 9.71M 1.77M 2026-03
Merck EUR 1.57B 49M 2026-06
Merck USD 2.89B 219M 2026-06
Northwest Biotherapeutics USD 6.54M 534K 2026-03
Novartis USD 3.24B 101M 2026-06
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 55.71M 4.87M 2026-06